HNSCC: Intratumoral Injection of T4 Immunotherapy Bypasses Homing (CME/CE)

(MedPage Today) -- Good safety profile, but no objective CR/PR in dose-escalation Phase I study
Source: MedPage Today Meeting Coverage - Category: Journals (General) Source Type: news